Market
Will Lenacapavir be adopted as standard PrEP in 10 countries by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
National health department announcements and health policy reports
Story
Twice-Yearly HIV Prevention Shot: 96% Effective in Men, 100% in Women
Dec 1, 2024, 12:50 PM
A new study has shown that Lenacapavir, a twice-yearly injectable pre-exposure prophylaxis (PrEP), is highly effective in preventing HIV infections, with a 96% reduction in risk for men and 100% effectiveness in women. Despite its potential, concerns have been raised about equitable access, cost-effectiveness, and adherence challenges. Gilead, the developer of the drug, has announced plans to allow the sale of generic versions of Lenacapavir in 120 countries with high HIV rates to address affordability issues. The World Health Organization (WHO) is currently reviewing the drug for initial approval, which could significantly impact HIV prevention strategies globally.
View original story
Similar markets
South Africa • 25%
USA • 25%
Other • 25%
UK • 25%
India • 25%
Other • 25%
South Africa • 25%
United States • 25%
